RIFAMYCIN SV CAS 6998-60-3 Rifaximin EP Impurity C

Model: MOS 18
Place of Origin: Zhejiang,China (Mainland)
Name: RIFAMYCIN SV
CAS: 6998-60-3
Molecular Formula: C37H47NO12
Brand: MOSINTER
Content: 98%min
Molecular Weight: 697.77
Synonyms 1: Rifaximin EP Impurity C
Synonyms 2: 17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-21-acetate

inquiry

skype basketAdd to Basket  Edit

Share |

Product Description

Payment & Shipping Terms Supply Capacity
Payment Terms:L/C, T/T, WUProduction Capacity:200KG/MONTH
Min. Order:1 KilogramPacking:As per request of...
Means of Transport:Ocean, Air, LandDelivery Date:within 7 days

RIFAMYCIN SV CAS 6998-60-3 Rifaximin EP Impurity C

Rifamycin sodium salt

A class of antibiotics produced by the Mediterranean strand. There is a strong antibacterial effect on gram-positive coccus and tuberculosis bacillus, and the effect of staphylococcus aureus is strong, but the effect on gram-negative bacteria is weaker. No cross resistance was found with other class antibiotics or anti-tuberculosis medicine.


The rifamycins are a group of antibiotics that are synthesized either naturally by the bacterium Amycolatopsis rifamycinica or artificially. They are a subclass of the larger family ofansamycins. Rifamycins are particularly effective against mycobacteria, and are therefore used to treat tuberculosis, leprosy, and mycobacterium avium complex (MAC) infections.

The rifamycin group includes the "classic" rifamycin medicine as well as the rifamycin derivatives rifampicin (or rifampin), rifabutin, rifapentine, rifalazil and rifaximin.


Rifamycins have been used for the treatment of many diseases, the most important one being HIV-related tuberculosis. A systematic review of clinical trials on alternative regimens for prevention of active tuberculosis in HIV-negative individuals with latent TB found that a weekly, directly observed regimen of rifapentine with isoniazid for three months was as effective as a daily, self-administered regimen of isoniazid for nine months. But the rifapentine-isoniazid regimen had higher rates of treatment completion and lower rates of hepatotoxicity. However, the rate of treatment-limiting adverse events was higher in the rifapentine-isoniazid regimen.

The rifamycins have a unique mechanism of action, selectively inhibiting bacterial DNA-dependent RNA polymerase, and show no cross-resistance with other antibiotics in clinical use. However, despite their activity against bacteria resistant to other antibiotics, the rifamycins themselves suffer from a rather high frequency of resistance. Because of this Rifampin, and other rifamycins, are typically used in combination with other antibacterial medicine. This is routinely practiced in TB therapy and serves to prevent the formation of mutants that are resistant to any of the medicinemedicine


The antibacterial activity of rifamycins relies on the inhibition of bacterial DNA-dependent RNA synthesis.This is due to the high affinity of rifamycins for the prokaryotic RNA polymerase. The selectivity of the rifamycins depends on the fact that they have a very poor affinity for the analogous mammalian enzyme. Crystal structure data of the antibiotic bound to RNA polymerase indicates that rifamycin blocks synthesis by causing strong steric clashes with the growing oligonucleotide ("steric-occlusion" mechanism). If rifamycin binds the polymerase after the chain extension process has started, no inhibition is observed on the biosynthesis, consistent with a steric-occlusion mechanism. Single step high level resistance to the rifamycins occurs as the result of a single amino acid change in the bacterial DNA dependent RNA polymerase.



Category: Other Chemical Products


«
Offline Showroom in USA
QR Code